Quantifying the Impact of Drug Exposure Misclassification due to Restrictive Drug Coverage in Administrative Databases: A Simulation Cohort Study

被引:16
作者
Gamble, John-Michael [2 ]
McAlister, Finlay A. [2 ,3 ,4 ]
Johnson, Jeffrey A. [2 ]
Eurich, Dean T. [1 ,2 ]
机构
[1] Univ Alberta, Li Ka Shing Ctr Hlth Res Innovat 2 040, Sch Publ Hlth, Edmonton, AB T6G 2E1, Canada
[2] Univ Alberta, ACHORD, Edmonton, AB T6G 2E1, Canada
[3] Mazankowski Alberta Heart Inst, Edmonton, AB, Canada
[4] Univ Alberta, Dept Med, Div Gen Internal Med, Edmonton, AB T6G 2E1, Canada
基金
加拿大健康研究院;
关键词
bias; formularies; mortality; pharmaceutical policy; pharmacoepidemiology simulation; THIAZOLIDINEDIONES; DISEASE;
D O I
10.1016/j.jval.2011.08.005
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: Drug exposure misclassification may occur in administrative databases when individuals obtain nonreimbursed drugs by paying "out-of-pocket" or via alternative drug coverage plans. We examined the apparent association between oral antidiabetic therapy and mortality by simulating the effects of restrictive drug coverage policies. Methods: Population-based cohort study of 12,272 new patients using oral antidiabetic agents were identified using the administrative databases of Saskatchewan Health, 1991 to 1996. We randomly misclassified 0% [base case], 10%, 25%, and 50% of known patients taking metformin according to either overt drug exposure (e. g., metformin users switched to nonusers) or time of metformin initiation (e.g., delayed capture of exposure); thereby simulating the use of a "non-formulary" or " special authorization" policy, respectively. We also simulated an age-dependent coverage policy, mimicking a policy restricted to seniors. Results: Metformin use was associated with lower mortality compared with sulfonylurea use in the base case (adjusted hazard ratio [aHR] 0.88, 95% confidence interval [CI] 0.78-0.99) and the nonformulary simulations. The special authorization simulations demonstrated, however, an increasing relative mortality hazard of metformin versus sulfonylurea exposure: aHR 0.96, 95% CI 0.96-0.97 and aHR 1.34, 95% CI 1.311.37, for 10% and 50% delays in coverage capture respectively when 50% of metformin users were misclassified. Age-dependent drug coverage had a variable impact on mortality risk compared with the base-case cohort; however, a new-user simulation with a 1-year washout revealed consistent results to the base-case analysis. Conclusion: Restrictive drug coverage policies may result in substantial drug exposure misclassification, potentially severely biasing the results of drug-outcome relationships using administrative databases.
引用
收藏
页码:191 / 197
页数:7
相关论文
共 18 条
[1]   Rational use of medicines -: an important issue in pharmaceutical policy [J].
Almarsdóttir, AB ;
Traulsen, JM .
PHARMACY WORLD & SCIENCE, 2005, 27 (02) :76-80
[2]  
[Anonymous], 2008, Modern epidemiology
[3]   Formulary Decisions: Then and Now [J].
Boucher, Bradley A. .
PHARMACOTHERAPY, 2010, 30 (06) :35S-41S
[4]   Thiazolidinediones and Fractures in Men and Women [J].
Dormuth, Colin R. ;
Carney, Greg ;
Carleton, Bruce ;
Bassett, Ken ;
Wright, Jarnes M. .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (15) :1395-1402
[5]  
Downey W, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P295
[6]   Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors [J].
Jacobus, S ;
Schneeweiss, S ;
Chan, KA .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (10) :695-702
[7]   Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes [J].
Johnson, JA ;
Majumdar, SR ;
Simpson, SH ;
Toth, EL .
DIABETES CARE, 2002, 25 (12) :2244-2248
[8]   Thiazolidinediones and cardiovascular outcomes in older patients with diabetes [J].
Lipscombe, Lorraine L. ;
Gomes, Tara ;
Levesque, Linda E. ;
Hux, Janet E. ;
Juurlink, David N. ;
Alter, David A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (22) :2634-2643
[9]   Importance of accurately identifying disease in studies using electronic health records [J].
Manuel, Douglas G. ;
Rosella, Laura C. ;
Stukel, Therese A. .
BMJ-BRITISH MEDICAL JOURNAL, 2010, 341 :440-443
[10]  
Paterson JM, 2008, CAN J PHARM, V15, pe106